Abstract: A method is provided for detecting a protein using a cyclodextrin covalently linked to at least one label. The cyclodextrin can associate with the protein by sequestering an aromatic amino acid side-chain of the protein in its hydrophobic cavity. After contacting the protein with the cyclodextrin, the label can be detected directly or can undergo a chemical interaction with a reagent to form a detectable product. The label can include an indole moiety, which can react with a halo-substituted organic compound upon exposure to UV light and thereby be rendered fluorescent. Alternatively, the label can include a biotin moiety, which can bind to a binding partner such as avidin, or variants thereof, to form a detectable molecular complex. A labeled cyclodextrin can be used in the present methods to detect a protein of interest in an electrophoresis gel or on a blotting membrane.
Type:
Grant
Filed:
August 8, 2014
Date of Patent:
March 15, 2016
Assignee:
BIO-RAD LABORATORIES, INC.
Inventors:
Clayton T. McKee, William Strong, Lee Olech, Thomas Berkelman, Christopher Belisle
Abstract: The invention provides methods for modulation interactions between MDL-1 and its binding partner, Gal9. Also provided are methods to screen for modulators of MDL-1/Gal9 interaction.
Type:
Grant
Filed:
June 19, 2015
Date of Patent:
March 15, 2016
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Barbara Joyce-Shaikh, Douglas C. Wilson, Daniel J. Cua, Drake M. LaFace, Joseph H. Phillips
Abstract: The present invention relates to a method for examining a person having symptoms and/or biomarkers indicating an autoimmune disease for the presence of atrophic gastritis. The biomarker combination, which diagnoses atrophic gastritis, acts also as a part of a biomarker panel that helps diagnosis and assessment of autoimmune disease as well. The invention relates also to products used in these methods.
Abstract: Provided are a method for accurately evaluating the differentiation status of stem cells by selectively staining only stem cells in an undifferentiated state, and a method for positively isolating only stem cells in an undifferentiated state. Specifically provided is a method for determining differentiation of a cell comprising a step of contacting a test cell with a probe comprising protein (A) or (B) below and a step of detecting the presence of binding of the probe to the test cell. The method for determining differentiation of a cell is capable of detecting the presence or absence of an undifferentiated stem cell in test cells by using a probe that specifically reacts with undifferentiated stem cells and detecting the presence of bonding to the test cell.
Type:
Grant
Filed:
February 27, 2013
Date of Patent:
March 8, 2016
Assignees:
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, WAKO PURE CHEMICAL INDUSTRIES, LTD.
Abstract: The present invention encompasses methods of identifying proteins and protein modifications of proteins specifically associated with a chromatin.
Type:
Grant
Filed:
November 15, 2013
Date of Patent:
March 8, 2016
Assignee:
BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
Inventors:
Alan J. Tackett, Stephanie Byrum, Sean Taverna
Abstract: This application describes an antibody that specifically binds to a synthetic oligomer (e.g., an oligonucleotide or oligopeptide) having a organic protecting group covalently bound thereto, which antibody does not bind to that synthetic oligomer when the organic protecting group is not covalently bound thereto. Methods of making and using such antibodies are also disclosed, along with cells for making such antibodies and articles carrying immobilized oligomers that can be used in assay procedures with such antibodies.
Type:
Grant
Filed:
February 27, 2014
Date of Patent:
March 1, 2016
Assignees:
Veri-Q, Inc., North Carolina State University
Inventors:
Paul F. Agris, Christopher D. J. Pearce, Lloyd G. Mitchell
Abstract: The present invention relates to a novel method of screening an agent for preventing or treating cancer using glycyl-tRNA synthetase (GRS) and cadherin (CDH). More particularly, it relates to a method of screening and test agent which modulates the binding level of GRS or their fragment with CDH. As can be seen foregoing, the present invention relates to a novel use of GRS and CDH and provides a method of screening an agent for preventing or treating cancer. The method may be used for developing novel agent for treatment of various cancer.
Type:
Grant
Filed:
April 10, 2014
Date of Patent:
March 1, 2016
Assignee:
Medicinal Bioconvergence Research Center
Abstract: Methods for assessing the condition of keratinized structures, including hair, in particular methods to determine the condition of keratinized structures in relation to suitability for analysis of analytes of interest in a test sample, are presented. The methods comprise contacting the keratinized structure with a non-proteolytic reducing agent and an optional proteolytic agent. The methods further include inspection of the hair sample, or measurement of free protein eluted from the keratinized structure, after reduction and optional proteolysis to determine condition prior to analyte identification and quantitation by known techniques such as immunoassays.
Type:
Grant
Filed:
March 20, 2015
Date of Patent:
February 16, 2016
Assignee:
Psychemedics Corporation
Inventors:
Virginia Hill, Michael I. Schaffer, Elvan Loni, Gary Neil Stowe
Abstract: The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins that are particularly advantageous for quantifying the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
Type:
Grant
Filed:
November 17, 2014
Date of Patent:
February 16, 2016
Assignee:
EXPRESSION PATHOLOGY, INC.
Inventors:
David B. Krizman, Wei-Li Liao, Sheeno Thyparambil, Todd Hembrough
Abstract: Specific peptides, and derived ionization characteristics of the peptides, from the Insulin Receptor protein (IR), and its isoforms IR-A and IR-B, that are particularly advantageous for quantifying the IR protein, IR-A isoform and/or IR-B isoform, directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and are selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
Type:
Grant
Filed:
July 10, 2014
Date of Patent:
February 9, 2016
Assignee:
Expression Pathology, Inc.
Inventors:
David B. Krizman, Wei-Li Liao, Sheeno Thyparambil, Todd Hembrough
Abstract: [Problem] The present invention provides a novel pathological marker of angiitis which serves as an alternative to MPO-ANCAs. [Means for Solution] According to one embodiment of the present invention, a method for testing angiitis which includes a step of detecting an antibody specifically recognizing a moesin in a biological sample is provided. In addition, according to another embodiment of the present invention, a reagent for testing angiitis which contains a substance that detects an antibody specifically recognizing a moesin in a biological sample is provided.
Type:
Grant
Filed:
May 12, 2011
Date of Patent:
January 26, 2016
Assignees:
National University Corporation Chiba University, Educational Foundation Jichi Medical University
Abstract: Several embodiments provided herein relate to methods of diagnosing asbestos exposure or mesothelioma. Several embodiments also relate to methods of differentiating whether a tumor of the lung is lung cancer or mesothelioma.
Type:
Grant
Filed:
June 7, 2012
Date of Patent:
January 26, 2016
Assignees:
University of Hawaii, New York University
Inventors:
Haining Yang, Michele Carbone, Harvey I. Pass
Abstract: A method for the detection of an early biomarker for assessing a change in renal status in a mammalian subject following a renal event. The method typically includes the steps of (a) providing a body fluid sample obtained from a mammalian subject; (b) analyzing the molecular weight of the proteins in the sample using proteome analysis; and (c) identifying the presence of a protein in the sample selected from the group consisting of a 6.4 kDa protein, a 28.5 kDa protein, a 33 kDa protein, a 44 kDa protein, a 67 kDa protein, and combinations thereof. The presence of one of these proteins can serve as an early biomarker for assessing a change in renal status. The levels of these proteins can be compared to predetermined levels, and thus provide a determination of the subject's renal status. The invention also includes a method of assessing the administration of aprotinin during cardio-pulmonary bypass surgery and provides for methods where the level of the 6.
Abstract: The present invention relates generally to methods for identifying organ-specific secreted proteins and for identifying organ-specific molecular blood fingerprints therefrom. As such, the present invention provides compositions comprising such proteins, detection reagents for detecting such proteins, and panels, and arrays for determining organ-specific molecular blood fingerprints.
Abstract: The invention relates to a method for detecting and measuring the presence of mono-nucleosomes and oligo-nucleosomes and the use of such measurements for the detection and diagnosis of disease.
Abstract: An in vitro method for the risk stratification of patients with stable arteriosclerosis, especially stable coronary artery disease, is disclosed wherein the concentration of procalcitonin is determined in the circulation of such patients using a highly sensitive PCT assay, and wherein within the range of PCT concentrations in the typical normal range of healthy individuals cutoff values are defined which distinguish groups of individual patients with stable arteriosclerosis in accordance with personal cardiac risk, and patients are allotted to one of said risk groups on the basis of their individual PCT concentrations.
Type:
Grant
Filed:
March 24, 2014
Date of Patent:
December 22, 2015
Assignee:
B.R.A.H.M.S. GmbH
Inventors:
Andreas Bergmann, Joachim Struck, Nils G. Morgenthaler, Jana Papassotiriou, Stefan Blankenberg, Karl Lackner, Hans Rupprecht, Christoph Bickel
Abstract: The present invention relates to a method of detecting the preovulatory LH peak in a biological sample obtained from mammals and a kit for applying the method of detection. The present invention finds application notably in the veterinary and medical areas.
Type:
Grant
Filed:
April 12, 2013
Date of Patent:
December 8, 2015
Assignee:
REPROPHARM
Inventors:
Jeremy Decourtye, Laurence Dupuy, Elodie Kara, Marie-Christine Maurel
Abstract: The present invention is directed to a method and apparatus that satisfies the need for a bioelectronic tongue for food allergy detection. The method of detecting concentration of food allergen incorporates antibodies into an electronic tongue to create a bioelectronic tongue. Additionally the method uses impedance, capacitance, and/or other related electrochemical methods for detecting analyte in complex media. Furthermore the method additionally includes methods to subtract out non-specific interactions. The method also subtracts non-specific interactions. The device/apparatus is a Bioelectronic Tongue for detecting allergen in diluted food samples. The device includes: a sensor array; an impedance or capacitance analyzer; a preprocessor; a feature extractor; a pattern recognizer; and an output device indicating an allergen concentration.
Type:
Grant
Filed:
September 3, 2009
Date of Patent:
December 1, 2015
Assignee:
CLARKSON UNIVERSITY
Inventors:
Ian Ivar Suni, Yin Huang, Stephanie Ann Caswell Schuckers
Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.
Type:
Grant
Filed:
June 20, 2011
Date of Patent:
December 1, 2015
Assignee:
ZORA BIOSCIENCES OY
Inventors:
Reijo Laaksonen, Kim Ekroos, Reini Hurme, Riikka Katainen
Abstract: Embodiments of the present disclosure provide methods for analyte sensors including methods for producing and using the analyte sensors, methods of detecting and/or measuring analyte activity, methods for characterizing analyte cellular activity, methods of detecting pH change in a system, method of controlling the concentration of an analyte in a system, fusion proteins, polynucleotides, and vectors corresponding to the analyte sensors, kits, and the like.
Type:
Grant
Filed:
April 15, 2013
Date of Patent:
December 1, 2015
Assignee:
GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
Inventors:
Jenny Jie Yang, Jin Zou, April L. Ellis Mitchem, Yiming Ye, Angela Holder, Yun Huang, Wei Yang, Michael Kirberger